Assumption | % Agreementa | Can’t judge (%) |
---|---|---|
It is likely that long-term treatment with vosoritide increases growth velocity until final height is reached in individuals with achondroplasia starting treatment between 2 years of age and puberty (Tanner stage > 1) | 92% | 8 |
It is likely that long-term treatment with vosoritide results in a greater final height in those starting at an earlier age than in those starting later | 100% | 8 |
A clinically meaningful positive impact of vosoritide on abnormal upper-to-lower body segment ratio is more likely in individuals with achondroplasia starting long-term treatment at an earlier age than in those starting treatment later | 92% | 8 |
Question | % Likely + Very likelyb |  |
---|---|---|
How likely do you consider long-term treatment with vosoritide to result in a clinically meaningful improvement in upper-to-lower body segment ratio in individuals with ACH starting between 2 years of age and puberty (Tanner stage > 1)? | 85% | 0 |